

**Cyclacel Pharmaceuticals, Inc.  
200 Connell Drive, Suite 1500  
Berkeley Heights, NJ 07922**

January 15, 2013

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Mail Stop 3561  
Washington, D.C. 20549

Re: **Cyclacel Pharmaceuticals, Inc.  
Registration Statement on Form S-1, as amended  
Originally Filed on December 26, 2012  
File No. 333-185674**

Ladies and Gentleman:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the "Company") hereby requests that the effectiveness of the above-captioned Registration Statement to Form S-1, as amended, be accelerated to Wednesday, January 16, 2013, at 09:30 a.m., EST, or as soon as thereafter practicable.

Please note that we acknowledge the following:

- should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
- the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Any questions should be addressed to Merav Gershtenman, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 935-3000.

Thank you very much.

Very truly yours,

CYCLACEL PHARMACEUTICALS, INC.

/s/Paul McBarron

Paul McBarron

Executive Vice President—Finance,

Chief Financial Officer and Chief Operating Officer

cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  
Joel I. Papernik, Esq.

---